On the combination itself. I found no human trial, no meta-analysis, and no scientific publication testing pomegranate plus dark chocolate as a combined intervention. Repeated searches for combination and synergy trials returned only studies of each food separately, or studies pairing pomegranate with unrelated interventions such as aerobic training or fermented sobya. The only source found that discusses the specific pairing is a fruit-industry website, which asserts synergy in general terms without citing any trial of the two foods together. There is no "reveal" by scientists here.

On cocoa flavanols and blood flow. This is the strongest supported element. The EFSA Panel concluded that a cause and effect relationship has been established between the consumption of cocoa flavanols and maintenance of normal endothelium-dependent vasodilation, with the authorised wording being that "Cocoa flavanols help maintain endothelium-dependent vasodilation, which contributes to normal blood flow" . To obtain the claimed effect, 200 mg of cocoa flavanols should be consumed daily, an amount that could be provided by 2.5 g of high-flavanol cocoa powder or 10 g of high-flavanol dark chocolate . The critical qualifier is "high-flavanol," which is a specific processed ingredient, not a supermarket bar.

On dark chocolate flavanol content. Cocoa's polyphenol content is real but fragile in processing. Alkalization has been shown to destroy polyphenols and significantly reduce antioxidant activity of cocoa powder, and during chocolate making the composition and content of polyphenols are further altered, mainly due to high temperatures and the presence of oxygen . Percentage cocoa on a label is a measure of total cocoa solids plus cocoa butter, not of surviving flavanols.

On pomegranate and plaque. The evidence is mixed and weaker than the post implies. The frequently cited supportive trial is Aviram et al., "Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation," Clin Nutr 2004 , a small study in patients with existing carotid stenosis. That paper later required a correction: a corrigendum notes the abstract incorrectly listed the blood pressure drop as 21% rather than 12% at one year . The larger, better-controlled follow-up found no benefit. A randomized, double-blind, parallel trial assessing pomegranate juice and carotid intima-media thickness progression in subjects at moderate coronary heart disease risk showed no significant influence of approximately 18 months of pomegranate juice consumption on CIMT progression in the overall study sample, with only post hoc exploratory analyses suggesting anything further, which the authors caution should be interpreted accordingly . Much of the plaque-reversal literature is preclinical: punicalagin and pomegranate extract have been shown to reverse endothelial dysfunction in preclinical investigations, and animal models of accelerated atherosclerosis show pomegranate can slow plaque progression . The mechanistic eNOS work was conducted in cultured human endothelial cells and animal models .

On the brain claim. This is where the post is most clearly contradicted by the best available evidence. COSMOS-Mind, a large randomized two-by-two factorial 3-year trial, tested whether daily cocoa extract containing 500 mg/day flavanols versus placebo improved cognition in older women and men, with a global cognitive composite as the primary outcome . The investigators found no cognitive benefit of daily cocoa extract administration containing 500 mg flavanols for 3 years . Note that 500 mg/day is far more flavanol than a realistic chocolate serving delivers. The supportive brain study is far smaller and measures a surrogate: a randomized, single-blinded, crossover, dose-comparison fMRI study examined the effects of cacao polyphenol-enriched dark chocolate, suggesting it may have beneficial effects such as helping maintain performance in long-lasting cognitive tasks . Brain imaging efficiency during a task is not protection from age-related decline.

METHODOLOGY AND CONTEXT

• Evidence hierarchy applied: For the vasodilation element, the top-tier source is a regulatory scientific opinion synthesizing RCTs (EFSA). For the cognition element, the top-tier source is a large multi-year RCT (COSMOS-Mind), which is null. For the plaque element, the top-tier source is the larger RCT (Davidson 2009), which is null on its primary comparison, against a small earlier positive trial (Aviram 2004) in a different, sicker population.
• Dose mismatch: EFSA's threshold is 200 mg cocoa flavanols per day from a high-flavanol product. The post's advice, "at least 70 percent cocoa," does not guarantee that dose. Flavanol content of retail bars varies by orders of magnitude depending on fermentation, roasting, and alkalization, and is not disclosed on labels.
• Population mismatch: The strongest pomegranate plaque data come from patients with existing carotid artery stenosis, not the general healthy audience the post addresses.
• Species and system mismatch: Several of the mechanistic statements about punicalagins, eNOS, and plaque reversal derive from cell culture and rodent work.
• No combination methodology exists to evaluate. There is no dose, no duration, no endpoint, and no control condition for "pomegranate plus dark chocolate," because no such trial was found.
• "Facts checked by @powermindset" is a self-referential label. It names no external verifier, no source list, and no methodology. It carries no evidentiary weight.